Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Through this partnership, UNLEASH and The Josh Bersin Company will introduce exclusive AI-focused workshops, featuring live immersive experiences of GalileoTM , the Essential AI Assistant for ...

The film follows a group of teenagers who plan the perfect heist by breaking into their middle school to alter their failing test grades.

This appointment is a testament to Dr. Lilly Ajarova’s strategic leadership and her significant contributions to the advancement of Uganda’s tourism sector within the global tourism arena.

Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings ... Joining me on today's call are Dave Ricks, Lilly's chair and CEO; Dr. Dan Skovronsky, chief scientific officer and ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

(Reuters) -Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.